ObsEva to Present at Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ObsEva SA (NASDAQ: OBSV), a biopharmaceutical company focusing on women's reproductive health, has scheduled corporate updates for the Wedbush PacGrow Healthcare Conference on August 11, 2021, at 8 a.m. EST, and the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 9 a.m. EST. Both presentations will be webcasted, with archived access available on ObsEva's website. ObsEva is developing therapies for conditions like endometriosis and uterine fibroids.
Details
News Market Reaction – OBSV
The recorded move for OBSV in the trading session of this news was -1.19%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GENEVA, Switzerland August 3, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporate update at the Wedbush PacGrow Healthcare Conference to be held August 10-11, 2021 and the Canaccord Genuity 41st Annual Growth Conference to be held August 10-12, 2021.
Details on the presentations can be found below.
Wedbush PacGrow Healthcare Conference
Date: Wednesday, August 11, 2021
Presentation Time: 8 a.m. EST
Webcast: Click Here
Canaccord Genuity 41st Annual Growth Conference
Date: Thursday, August 12, 2021
Presentation Time: 9 a.m. EST
Webcast: Click Here
The presentations and archived webcasts will also be accessible under "Events Calendar" in the investors section of ObsEva's website.
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
For further information, please contact:
CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617)-435-6602
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.